Literature DB >> 12429586

The novel antagonist 3-CBW discriminates between kainate receptors expressed on neonatal rat motoneurones and those on dorsal root C-fibres.

Julia C A More1, Helen M Troop, David E Jane.   

Abstract

1. The natural product willardiine is a selective AMPA receptor agonist. We report that an N(3)-substituted analogue of willardiine, (S)-3-(4-carboxybenzyl)willardiine 3-CBW, antagonizes AMPA and kainate receptors expressed on motoneurones and dorsal root C-fibres, respectively. 2. Reduction of the fast component of the dorsal root-evoked ventral root potential (fDR-VRP) has been used as a novel method to compare AMPA receptor antagonists. 3-CBW, NBQX and GYKI53655 depressed the fDR-VRP with IC(50) values of 10.3+/-2.4, 0.214+/-0.043 and 4.03+/-0.31 micro M, respectively. That 3-CBW depressed the fDR-VRP by acting at AMPA and not metabotropic glutamate receptors was demonstrated by the lack of effect of LY341495 (100 micro M). 3. The Schild plot for antagonism of responses to (S)-5-fluorowillardiine on motoneurones by 3-CBW had a slope of 1.11+/-0.13 giving a pA(2) value of 4.48. The Schild plot for antagonism of kainate responses on the dorsal root by 3-CBW had a slope of 1.05+/-0.05 giving a pA(2) value of 4.96. 4. On neonatal rat motoneurones 3-CBW (200 micro M) almost completely abolished responses to AMPA while responses to NMDA, kainate and DHPG were 101.6+/-11.6%, 39.4+/-5.8% and 110.5+/-9.0% of control, respectively. 3-CBW can therefore be used to isolate kainate receptor responses from those mediated by AMPA receptors. 5 3-CBW antagonized kainate-induced responses on dorsal root C-fibres with a pA(2) value of 4.96 whereas kainate receptor mediated responses (isolated by including GYKI53655 in the medium) on motoneurones were not completely blocked by 200 micro M 3-CBW, substantiating evidence that kainate receptors on neonatal rat motoneurones differ from those on dorsal root C-fibres.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12429586      PMCID: PMC1573580          DOI: 10.1038/sj.bjp.0704957

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  39 in total

1.  Cloning of a novel glutamate receptor subunit, GluR5: expression in the nervous system during development.

Authors:  B Bettler; J Boulter; I Hermans-Borgmeyer; A O'Shea-Greenfield; E S Deneris; C Moll; U Borgmeyer; M Hollmann; S Heinemann
Journal:  Neuron       Date:  1990-11       Impact factor: 17.173

Review 2.  Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists.

Authors:  J C Watkins; P Krogsgaard-Larsen; T Honoré
Journal:  Trends Pharmacol Sci       Date:  1990-01       Impact factor: 14.819

3.  The differential expression of 16 NMDA and non-NMDA receptor subunits in the rat spinal cord and in periaqueductal gray.

Authors:  T R Tölle; A Berthele; W Zieglgänsberger; P H Seeburg; W Wisden
Journal:  J Neurosci       Date:  1993-12       Impact factor: 6.167

4.  2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia.

Authors:  M J Sheardown; E O Nielsen; A J Hansen; P Jacobsen; T Honoré
Journal:  Science       Date:  1990-02-02       Impact factor: 47.728

5.  Pharmacological characterization of non-NMDA subtypes of glutamate receptor in the neonatal rat hemisected spinal cord in vitro.

Authors:  S Zeman; D Lodge
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

6.  A comparison of the actions of agonists and antagonists at non-NMDA receptors of C fibres and motoneurones of the immature rat spinal cord in vitro.

Authors:  P Pook; F Brugger; N S Hawkins; K C Clark; J C Watkins; R H Evans
Journal:  Br J Pharmacol       Date:  1993-01       Impact factor: 8.739

7.  Activation and desensitization of AMPA/kainate receptors by novel derivatives of willardiine.

Authors:  D K Patneau; M L Mayer; D E Jane; J C Watkins
Journal:  J Neurosci       Date:  1992-02       Impact factor: 6.167

8.  The primary afferent depolarizing action of kainate in the rat.

Authors:  S G Agrawal; R H Evans
Journal:  Br J Pharmacol       Date:  1986-02       Impact factor: 8.739

9.  Novel class of amino acid antagonists at non-N-methyl-D-aspartic acid excitatory amino acid receptors. Synthesis, in vitro and in vivo pharmacology, and neuroprotection.

Authors:  P Krogsgaard-Larsen; J W Ferkany; E O Nielsen; U Madsen; B Ebert; J S Johansen; N H Diemer; T Bruhn; D T Beattie; D R Curtis
Journal:  J Med Chem       Date:  1991-01       Impact factor: 7.446

10.  An in vitro mature spinal cord preparation from the rat.

Authors:  S K Long; R H Evans; L Cull; F Krijzer; P Bevan
Journal:  Neuropharmacology       Date:  1988-05       Impact factor: 5.250

View more
  4 in total

Review 1.  Medicinal chemistry of competitive kainate receptor antagonists.

Authors:  Ann M Larsen; Lennart Bunch
Journal:  ACS Chem Neurosci       Date:  2010-12-10       Impact factor: 4.418

2.  Structural requirements for novel willardiine derivatives acting as AMPA and kainate receptor antagonists.

Authors:  Julia C A More; Helen M Troop; Nigel P Dolman; David E Jane
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

3.  Actions of LY341495 on metabotropic glutamate receptor-mediated responses in the neonatal rat spinal cord.

Authors:  Patrick A Howson; David E Jane
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

4.  ACET is a highly potent and specific kainate receptor antagonist: characterisation and effects on hippocampal mossy fibre function.

Authors:  Sheila L Dargan; Vernon R J Clarke; Gregory M Alushin; John L Sherwood; Robert Nisticò; Zuner A Bortolotto; Ann M Ogden; David Bleakman; Andrew J Doherty; David Lodge; Mark L Mayer; Stephen M Fitzjohn; David E Jane; Graham L Collingridge
Journal:  Neuropharmacology       Date:  2008-08-22       Impact factor: 5.250

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.